[dideuterio-[2-(2-dibenzofuran-4-ylbenzimidazol-1-yl)phenyl]methyl]-trimethylsilane
C29H26N2OSi — CID 168730895
Data last refreshed: (MolForge compound catalog, from PubChem)
About [dideuterio-[2-(2-dibenzofuran-4-ylbenzimidazol-1-yl)phenyl]methyl]-trimethylsilane
[dideuterio-[2-(2-dibenzofuran-4-ylbenzimidazol-1-yl)phenyl]methyl]-trimethylsilane (PubChem CID 168730895) has the molecular formula C29H26N2OSi and a molecular weight of 448.64 g/mol. Its IUPAC name is [dideuterio-[2-(2-dibenzofuran-4-ylbenzimidazol-1-yl)phenyl]methyl]-trimethylsilane.
Molecular Properties
| Compound Name | [dideuterio-[2-(2-dibenzofuran-4-ylbenzimidazol-1-yl)phenyl]methyl]-trimethylsilane |
|---|---|
| PubChem CID | 168730895 |
| Molecular Formula | C29H26N2OSi |
| Molecular Weight | 448.64 g/mol |
| Exact Mass | 448.19 |
| IUPAC Name | [dideuterio-[2-(2-dibenzofuran-4-ylbenzimidazol-1-yl)phenyl]methyl]-trimethylsilane |
| SMILES | [2H]C([2H])(c1ccccc1-n1c(-c2cccc3c2oc2ccccc23)nc2ccccc21)[Si](C)(C)C |
| InChI | InChI=1S/C29H26N2OSi/c1-33(2,3)19-20-11-4-7-16-25(20)31-26-17-8-6-15-24(26)30-29(31)23-14-10-13-22-21-12-5-9-18-27(21)32-28(22)23/h4-18H,19H2,1-3H3/i19D2 |
| InChIKey | YWMOONKCRFERAH-FKUWIZNHSA-N |
| XLogP | 8.01 |
| TPSA | 30.96 Ų |
| H-Bond Donors | |
| H-Bond Acceptors | 3 |
| Rotatable Bonds | 4 |
| Heavy Atoms | 33 |
| Complexity | — |
Lipinski Rule of Five
1 violation
| Rule | Value |
|---|---|
| MW ≤ 500 | 448.64 |
| LogP ≤ 5 | 8.01 |
| H-Bond Donors ≤ 5 | 0 |
| H-Bond Acceptors ≤ 10 | 3 |
Computed Properties (RDKit)
| Structural Alerts | {'alert_name': 'heavy_metal', 'substructure': 'N/A'} |
|---|
Frequently Asked Questions
Browse: Molecules A–Z · all molecules A–Z · drugs A–Z · protein targets A–Z.
Sources
- PubChem CID 168730895 — identifiers, structure, computed properties (public domain)
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.